secwatch.observer — SEC 8-K summary
======================================

Issuer:     Twist Bioscience Corp (TWST)
CIK:        0001581280
Form:       8-K
Filed at:   2025-08-04T23:59:59+00:00
Accession:  0001581280-25-000006
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Twist Bioscience reports record Q3 revenue $96.1M (+18% YoY); swings to GAAP net income $20.4M
--------------------------------------------------------------------------------

- Record revenue $96.1M, up 18% YoY; NGS revenue grew 27% to $55.3M.
- Gross margin improved to 53.4% from 43.3% YoY; net income $20.4M ($0.34/share) vs loss $85.6M.
- FY2025 revenue guidance raised to $374-376M; gross margin guidance raised to 50.5%-51%.
- Adjusted EBITDA loss narrowed to $(8.0)M from $(22.0)M; expect breakeven by end of FY2026.
- Added ~184 net new customers; shipped 237,000 genes, up 12% YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1581280/000158128025000006/0001581280-25-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1581280/000158128025000006/twist-20250804.htm
  HTML page:      https://secwatch.observer/filing/0001581280-25-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer